Etiologies of Melanoma Development and Prevention Measures: A Review of the Current Evidence
Authors:
- Amir Reza DjavidADAmir Reza Djavid
- Connor StonesiferCSConnor Stonesifer
- Benjamin T. FullertonBFBenjamin T. Fullerton
- Samuel W. WangSWSamuel W. Wang
- Marlene A. TartaroMTMarlene A. Tartaro
- Bradley D. KwintaBKBradley D. Kwinta
- Joseph M. GrimesJGJoseph M. Grimes
- Larisa J. GeskinLarisa J. Geskin
- Yvonne M. SaengerYSYvonne M. Saenger
Open Access
Abstract
(1) Melanoma is the most aggressive dermatologic malignancy, with an estimated 106,110 new cases to be diagnosed in 2021. The annual incidence rates continue to climb, which underscores the critical importance of improving the methods to prevent this disease. The interventions to assist with melanoma prevention vary and typically include measures such as UV avoidance and the use of protective clothing, sunscreen, and other chemopreventive agents. However, the evidence is mixed surrounding the use of these and other interventions. This review discusses the heritable etiologies underlying melanoma development before delving into the data surrounding the preventive methods highlighted above. (2) A comprehensive literature review was performed to identify the clinical trials, observational studies, and meta-analyses pertinent to melanoma prevention and incidence. Online resources were queried to identify epidemiologic and clinical trial information. (3) Evidence exists to support population-wide screening programs, the proper use of sunscreen, and community-targeted measures in the prevention of melanoma. Clinical evidence for the majority of the proposed preventive chemotherapeutics is presently minimal but continues to evolve. (4) Further study of these chemotherapeutics, as well as improvement of techniques in artificial intelligence and imaging techniques for melanoma screening, is warranted for continued improvement of melanoma prevention.Keywords
This publication has 161 references indexed in Scilit:
- BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITsJournal of Translational Medicine, 2012
- Randomized controlled trial of acitretin versus placebo in patients at high‐risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251)Cancer, 2011
- Chemoprevention of Nonmelanoma Skin Cancer With Celecoxib: A Randomized, Double-Blind, Placebo-Controlled TrialJNCI: Journal of the National Cancer Institute, 2010
- Genetics of pigmentation in skin cancer — A reviewMutation Research - Reviews in Mutation Research, 2010
- Basal Cell Carcinoma Chemoprevention with Nonsteroidal Anti-inflammatory Drugs in Genetically Predisposed PTCH1+/− Humans and MiceCancer Prevention Research, 2010
- Selection criteria for genetic assessment of patients with familial melanomaJournal of the American Academy of Dermatology, 2009
- Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factorsEuropean Journal of Cancer, 2005
- Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naeviEuropean Journal of Cancer, 2005
- Clinical and histopathological features of malignant melanoma in germline CDKN2A mutation familiesMelanoma Research, 2002
- Prevention of Skin Cancer in Xeroderma Pigmentosum with the Use of Oral IsotretinoinNew England Journal of Medicine, 1988